Cargando…
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
Individual response to immune checkpoint inhibitors (ICIs) is currently unpredictable in patients with melanoma. Recent findings highlight a striking improvement in the clinical outcomes of overweight/obese patients treated with ICIs, which seems driven, at least in part, by programmed cell death pr...
Autores principales: | Incorvaia, Lorena, Rinaldi, Gaetana, Badalamenti, Giuseppe, Cucinella, Alessandra, Brando, Chiara, Madonia, Giorgio, Fiorino, Alessia, Pipitone, Angela, Perez, Alessandro, Li Pomi, Federica, Galvano, Antonio, Gristina, Valerio, Barraco, Nadia, Bono, Marco, Bazan Russo, Tancredi Didier, Toia, Francesca, Cordova, Adriana, Fanale, Daniele, Russo, Antonio, Bazan, Viviana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936535/ https://www.ncbi.nlm.nih.gov/pubmed/36818688 http://dx.doi.org/10.1177/17588359231151845 |
Ejemplares similares
-
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019) -
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
por: Badalamenti, Giuseppe, et al.
Publicado: (2022) -
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
por: Fanale, Daniele, et al.
Publicado: (2021) -
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020) -
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
por: Bono, M., et al.
Publicado: (2021)